Copyright Reports & Markets. All rights reserved.

Valvular Heart Disease Treatment-Global Market Status and Trend Report 2013-2023

Request for Sample of this report
Buy now

Table of Contents

    Chapter 1 Overview of Valvular Heart Disease Treatment

    • 1.1 Definition of Valvular Heart Disease Treatment in This Report
    • 1.2 Commercial Types of Valvular Heart Disease Treatment
      • 1.2.1 Cardiac Catheterization
      • 1.2.2 Electrocardiogram (ECG)
      • 1.2.3 Chest X-Ray
      • 1.2.4 Stress Test
      • 1.2.5 Others
    • 1.3 Downstream Application of Valvular Heart Disease Treatment
      • 1.3.1 Hospital & Clinics
      • 1.3.2 Ambulatory Surgical Centers
      • 1.3.3 Research Institutes
    • 1.4 Development History of Valvular Heart Disease Treatment
    • 1.5 Market Status and Trend of Valvular Heart Disease Treatment 2013-2023
      • 1.5.1 Global Valvular Heart Disease Treatment Market Status and Trend 2013-2023
      • 1.5.2 Regional Valvular Heart Disease Treatment Market Status and Trend 2013-2023

    Chapter 2 Global Market Status and Forecast by Regions

    • 2.1 Market Development of Valvular Heart Disease Treatment 2013-2017
    • 2.2 Production Market of Valvular Heart Disease Treatment by Regions
      • 2.2.1 Production Volume of Valvular Heart Disease Treatment by Regions
      • 2.2.2 Production Value of Valvular Heart Disease Treatment by Regions
    • 2.3 Demand Market of Valvular Heart Disease Treatment by Regions
    • 2.4 Production and Demand Status of Valvular Heart Disease Treatment by Regions
      • 2.4.1 Production and Demand Status of Valvular Heart Disease Treatment by Regions 2013-2017
      • 2.4.2 Import and Export Status of Valvular Heart Disease Treatment by Regions 2013-2017

    Chapter 3 Global Market Status and Forecast by Types

    • 3.1 Production Volume of Valvular Heart Disease Treatment by Types
    • 3.2 Production Value of Valvular Heart Disease Treatment by Types
    • 3.3 Market Forecast of Valvular Heart Disease Treatment by Types

    Chapter 4 Global Market Status and Forecast by Downstream Industry

    • 4.1 Demand Volume of Valvular Heart Disease Treatment by Downstream Industry
    • 4.2 Market Forecast of Valvular Heart Disease Treatment by Downstream Industry

    Chapter 5 Market Driving Factor Analysis of Valvular Heart Disease Treatment

    • 5.1 Global Economy Situation and Trend Overview
    • 5.2 Valvular Heart Disease Treatment Downstream Industry Situation and Trend Overview

    Chapter 6 Valvular Heart Disease Treatment Market Competition Status by Major Manufacturers

    • 6.1 Production Volume of Valvular Heart Disease Treatment by Major Manufacturers
    • 6.2 Production Value of Valvular Heart Disease Treatment by Major Manufacturers
    • 6.3 Basic Information of Valvular Heart Disease Treatment by Major Manufacturers
      • 6.3.1 Headquarters Location and Established Time of Valvular Heart Disease Treatment Major Manufacturer
      • 6.3.2 Employees and Revenue Level of Valvular Heart Disease Treatment Major Manufacturer
    • 6.4 Market Competition News and Trend
      • 6.4.1 Merger, Consolidation or Acquisition News
      • 6.4.2 Investment or Disinvestment News
      • 6.4.3 New Product Development and Launch

    Chapter 7 Valvular Heart Disease Treatment Major Manufacturers Introduction and Market Data

    • 7.1 LivaNova PLC
      • 7.1.1 Company profile
      • 7.1.2 Representative Valvular Heart Disease Treatment Product
      • 7.1.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of LivaNova PLC
    • 7.2 Neovasc Inc.
      • 7.2.1 Company profile
      • 7.2.2 Representative Valvular Heart Disease Treatment Product
      • 7.2.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Neovasc Inc.
    • 7.3 Medtronic
      • 7.3.1 Company profile
      • 7.3.2 Representative Valvular Heart Disease Treatment Product
      • 7.3.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Medtronic
    • 7.4 B. Braun Melsungen AG
      • 7.4.1 Company profile
      • 7.4.2 Representative Valvular Heart Disease Treatment Product
      • 7.4.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of B. Braun Melsungen AG
    • 7.5 Abbott Laboratories
      • 7.5.1 Company profile
      • 7.5.2 Representative Valvular Heart Disease Treatment Product
      • 7.5.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Abbott Laboratories
    • 7.6 Boston Scientific Corp.
      • 7.6.1 Company profile
      • 7.6.2 Representative Valvular Heart Disease Treatment Product
      • 7.6.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Boston Scientific Corp.
    • 7.7 Symetis SA
      • 7.7.1 Company profile
      • 7.7.2 Representative Valvular Heart Disease Treatment Product
      • 7.7.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Symetis SA
    • 7.8 Edwards Lifesciences Corporation
      • 7.8.1 Company profile
      • 7.8.2 Representative Valvular Heart Disease Treatment Product
      • 7.8.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Edwards Lifesciences Corporation
    • 7.9 CryoLife Inc.
      • 7.9.1 Company profile
      • 7.9.2 Representative Valvular Heart Disease Treatment Product
      • 7.9.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of CryoLife Inc.
    • 7.10 Micro Interventional Devices
      • 7.10.1 Company profile
      • 7.10.2 Representative Valvular Heart Disease Treatment Product
      • 7.10.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Micro Interventional Devices
    • 7.11 Braile Biomédica
      • 7.11.1 Company profile
      • 7.11.2 Representative Valvular Heart Disease Treatment Product
      • 7.11.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Braile Biomédica
    • 7.12 Jenavalve Technology
      • 7.12.1 Company profile
      • 7.12.2 Representative Valvular Heart Disease Treatment Product
      • 7.12.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Jenavalve Technology
    • 7.13 Lepu Medical Technology Co.
      • 7.13.1 Company profile
      • 7.13.2 Representative Valvular Heart Disease Treatment Product
      • 7.13.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Lepu Medical Technology Co.
    • 7.14 TTK Healthcare Limited
      • 7.14.1 Company profile
      • 7.14.2 Representative Valvular Heart Disease Treatment Product
      • 7.14.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of TTK Healthcare Limited
    • 7.15 Colibri Heart Valve
      • 7.15.1 Company profile
      • 7.15.2 Representative Valvular Heart Disease Treatment Product
      • 7.15.3 Valvular Heart Disease Treatment Sales, Revenue, Price and Gross Margin of Colibri Heart Valve

    Chapter 8 Upstream and Downstream Market Analysis of Valvular Heart Disease Treatment

    • 8.1 Industry Chain of Valvular Heart Disease Treatment
    • 8.2 Upstream Market and Representative Companies Analysis
    • 8.3 Downstream Market and Representative Companies Analysis

    Chapter 9 Cost and Gross Margin Analysis of Valvular Heart Disease Treatment

    • 9.1 Cost Structure Analysis of Valvular Heart Disease Treatment
    • 9.2 Raw Materials Cost Analysis of Valvular Heart Disease Treatment
    • 9.3 Labor Cost Analysis of Valvular Heart Disease Treatment
    • 9.4 Manufacturing Expenses Analysis of Valvular Heart Disease Treatment

    Chapter 10 Marketing Status Analysis of Valvular Heart Disease Treatment

    • 10.1 Marketing Channel
      • 10.1.1 Direct Marketing
      • 10.1.2 Indirect Marketing
      • 10.1.3 Marketing Channel Development Trend
    • 10.2 Market Positioning
      • 10.2.1 Pricing Strategy
      • 10.2.2 Brand Strategy
      • 10.2.3 Target Client
    • 10.3 Distributors/Traders List

    Chapter 11 Report Conclusion

      Chapter 12 Research Methodology and Reference

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources

      Report Summary

      Valvular Heart Disease Treatment-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Valvular Heart Disease Treatment industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

      Worldwide and Regional Market Size of Valvular Heart Disease Treatment 2013-2017, and development forecast 2018-2023
      Main manufacturers/suppliers of Valvular Heart Disease Treatment worldwide, with company and product introduction, position in the Valvular Heart Disease Treatment market
      Market status and development trend of Valvular Heart Disease Treatment by types and applications
      Cost and profit status of Valvular Heart Disease Treatment, and marketing status
      Market growth drivers and challenges

      The report segments the global Valvular Heart Disease Treatment market as:

      Global Valvular Heart Disease Treatment Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
      North America
      Europe
      China
      Japan
      Rest APAC
      Latin America

      Global Valvular Heart Disease Treatment Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
      Cardiac Catheterization
      Electrocardiogram (ECG)
      Chest X-Ray
      Stress Test
      Others

      Global Valvular Heart Disease Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
      Hospital & Clinics
      Ambulatory Surgical Centers
      Research Institutes

      Global Valvular Heart Disease Treatment Market: Manufacturers Segment Analysis (Company and Product introduction, Valvular Heart Disease Treatment Sales Volume, Revenue, Price and Gross Margin):
      LivaNova PLC
      Neovasc Inc.
      Medtronic
      B. Braun Melsungen AG
      Abbott Laboratories
      Boston Scientific Corp.
      Symetis SA
      Edwards Lifesciences Corporation
      CryoLife Inc.
      Micro Interventional Devices
      Braile Biomédica
      Jenavalve Technology
      Lepu Medical Technology Co.
      TTK Healthcare Limited
      Colibri Heart Valve

      In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
      Buy now